Actos study points to reduction in heart attacks, strokes

A new study shows that Takeda's Actos helped patients lower blood sugar while significantly reducing the number of heart attacks, strokes and death. Actos (pioglitazone HCl) is an insulin sensitizer, working in patients with type 2 diabetes to make their cells more sensitive to insulin. The broader health impact may well expand the drug's use and prove a boon to other insulin sensitizers as well, including Avandia from GlaxoSmithKline.

- read this press release for more